Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 12/20 | 0.66 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493621 | 1.00 | KCNA5 (0.66) | KCNA5KCND3POLBGAAKDM4E | |
| SCHEMBL12195879 | 1.00 | KCNA5 (0.66) | KCNA5KCND3POLBGAAKDM4E | |
| SCHEMBL12052092 | 0.93 | KCNA5 (0.58) | KCNA5KCND3POLBGAAKDM4E | |
| SCHEMBL12194953 | 0.92 | KCNA5 (0.67) | KCNA5KCND3POLBGAAKDM4E | |
| SCHEMBL12194957 | 0.91 | KCNA5 (0.53) | KCNA5KCND3POLBGAAKDM4E | |
| SCHEMBL4520563 | 0.91 | KCNA5 (0.53) | KCNA5KCND3POLBGAAKDM4E | |
| SCHEMBL2472879 | 0.91 | KCNA5 (0.70) | KCNA5KCND3KDM4EALDH1A1KCNH2 | |
| SCHEMBL2493518 | 0.91 | KCNA5 (0.70) | KCNA5KCND3KDM4EALDH1A1KCNH2 | |
| SCHEMBL2476259 | 0.91 | KCNA5 (0.70) | KCNA5KCND3KDM4EALDH1A1KCNH2 | |
| SCHEMBL12194982 | 0.91 | KCNA5 (0.70) | KCNA5KCND3KDM4EALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080543-B2 | Pyridine derivative potassium channel inhibitors | MERCK SHARP & DOHME (US) | 2011-12-20 | — | — | US | claimed |
| EP-1994029-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | claimed |
| US-20090069283-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | claimed |
| EP-1994029-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007089678-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-8080543-B2 | Pyridine derivative potassium channel inhibitors | MERCK SHARP & DOHME (US) | 2011-12-20 | — | — | US | disclosed |
| EP-1994029-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090069283-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069283-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | KCNA5 14/4885KCND3 38/4885POLB 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.